{"meshTagsMajor":["Mutation"],"meshTags":["Proto-Oncogene Proteins B-raf","Male","Humans","Indoles","Antineoplastic Agents","Neoplasms","Histiocytosis","Carcinoma, Non-Small-Cell Lung","Mutation","Sulfonamides","Female"],"meshMinor":["Proto-Oncogene Proteins B-raf","Male","Humans","Indoles","Antineoplastic Agents","Neoplasms","Histiocytosis","Carcinoma, Non-Small-Cell Lung","Sulfonamides","Female"],"genes":["BRAF V600"],"publicationTypes":["Comment","News"],"abstract":"In a phase II basket trial, vemurafenib, an enzyme inhibitor prescribed for certain BRAF V600-mutant melanomas, proved effective in some nonmelanoma cancers that also carried a BRAF V600 mutation. ","title":"Melanoma Drug Works in Other Tumors.","pubmedId":"26385779"}